MD Anderson and Radiopharm Theranostics launch joint venture to develop novel radiopharmaceuticals
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint venture created to develop novel radiopharmaceutical therapeutic products for cancer.
Radiopharm Ventures brings together MD Anderson’s innovative and proprietary technologies in antigen discovery and molecular imaging with Radiopharm’s expertise in developing radiopharmaceutical products...
Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses
Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating...
RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in...
MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
The agreement brings together MD Anderson’s clinical trials expertise and infrastructure with Virogin’s innovative pipeline of investigational oncolytic viruses. The five-year...
